Deans' stroke musings: Can Nerinetide Enhance Stroke Outcomes Without Thrombolysis?

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, December 24, 2025

Can Nerinetide Enhance Stroke Outcomes Without Thrombolysis?

Ask your fuckingly incompetent? doctor why NOTHING has been done with this in the last 5+ years! No excuses are allowed! So you're contradicting this from February 2025?

Nerinetide shows promise in stroke treatment meta-analysis February 2025

nerinetide (12 posts to February 2020)

Can Nerinetide Enhance Stroke Outcomes Without Thrombolysis?

OBJECTIVE

This systematic review and meta-analysis aimed to evaluate the safety and efficacy of intravenous (IV) nerinetide in acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT) without prior or concurrent IV thrombolysis (IVT).

METHODS

A systematic search of PubMed, Web of Science, and Scopus was conducted through March 15, 2025, identifying randomized controlled trials (RCTs) comparing EVT plus nerinetide versus EVT plus placebo without IVT. Screening and data extraction were performed independently by two reviewers, with conflicts resolved by a third. Risk of bias was assessed using RoB 2.0. Data were synthesized using RevMan 5.4 with random-effects models, and heterogeneity was evaluated via chi-square and I² statistics.

RESULTS

Three RCTs comprising 726 patients in the IV nerinetide group and 668 in the placebo group were included. Nerinetide did not significantly improve functional outcomes: 90-day modified Rankin Scale (mRS) 0-1 (RR: 1.02, 95% CI: [0.71, 1.47], P = 0.92) and mRS 0-2 (RR: 1.07, 95% CI: [0.93, 1.22], P = 0.35). No significant differences were observed in 90-day mortality (RR: 0.89, 95% CI: [0.60, 1.34], P = 0.59) or adverse events, including symptomatic intracranial hemorrhage (RR: 0.80, 95% CI: [0.44, 1.45], P = 0.46).

CONCLUSION

Nerinetide administration during EVT in AIS patients without IVT did not significantly improve functional independence, survival, or safety outcomes compared to placebo. Although preclinical data supported neuroprotection, clinical benefits were not observed, highlighting the challenges in translating neuroprotective strategies into effective stroke therapies.